Chugai's Bispecific Antibody Emicizumab to Present Results of Two Pivotal Phase lll Studies at ISTH
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced results from two global phase lll studies for Chugai’s bispecific antibody emicizumab (ACE910): the primary analysis of HAVEN 1 study (NCT02622321) and the interim analysis of HAVEN 2 study (NCT02795767). The data will be presented on July 10 at the upcoming 26th International Society on Thrombosis and Haemostasis (ISTH) Meeting in Berlin, Germany (July 8 to 13). Both studies were conducted in haemophilia A with inhibitors, while HAVEN 1 is for adult and adolescent patients and HAVEN 2 is for paediatric patients.
HAVEN 1 Study
HAVEN 1 is a randomised, multicentre, open-label, global phase III study evaluating the efficacy, safety, and pharmacokinetics of emicizumab once-weekly subcutaneous injection for 24 weeks or longer in adults and adolescents (12 years of age or older) with haemophilia A with inhibitors to factor VIII.
Study design n=109
- Patients previously treated with on-demand bypassing agents (BPAs) were randomised in a 2:1 fashion to Arm A or B
|Arm A (n=35):||emicizumab once-weekly dosing|
|Arm B (n=18):||no prophylaxis (on-demand BPA)|
- Patients previously treated with prophylactic BPA
|Arm C (n=49):||emicizumab once-weekly dosing|
- Patients who participated in a forgoing Non-Interventional Study (NIS) and previously on BPA (on-demand or prophylactic)
|Arm D:||emicizumab once-weekly dosing|
On-demand use of BPAs was allowed to treat breakthrough bleeds per protocol in all arms.
Summary of results
- The primary endpoint was achieved with a statistically significant reduction in bleed rate of 87% (risk rate [RR]=0.13, p<0.0001) in treated bleeds with emicizumab (Arm A) compared with on-demand treatment with BPAs (Arm B). All secondary endpoints were also achieved with consistent reductions in bleed rates.
[Major secondary endpoints and reduction rate (%) compared with on-demand BPAs]
|All bleeds:||(80%, RR=0.20, p<0.0001)|
|Treated spontaneous bleeds:||(92%, RR=0.08, p≤0.0001)|
|Treated joint bleeds:||(89%, RR=0.11, p=0.0050)|
|Treated target joint bleeds:||(95%, RR=0.05, p=0.0002)|
- After a median observation time of 31 weeks, 62.9% of patients receiving emicizumab experienced zero treated bleeds (Arm A) compared to 5.6% of those receiving on-demand BPAs (Arm B).
- Results also showed a statistically significant improvement in health-related quality of life (HRQoL) measured at 25 weeks with emicizumab (Arm A) compared to on-demand BPAs (Arm B).
- Among patients who had previously received prophylactic use of BPAs and then received emicizumab (Arm C), 24 patients had participated in the foregoing NIS, which was conducted without emicizumab. An intra-patient analysis in this group showed a 79% (RR=0.21, p=0.0003) reduction in treated bleeds receiving emicizumab compared to their prior prophylaxis with BPAs.
- Adverse events (AEs) occurring in 5% or more of patients treated with emicizumab were injection site reactions, headache, fatigue, upper respiratory tract infection and arthralgia.
- Serious adverse events were reported with thromboembolic events (TE) in two patients and thrombotic microangiopathy (TMA) in three patients (one patient experienced TMA after the clinical data cut off for primary analysis) while receiving emicizumab prophylaxis. The TE and TMA events were associated with repeated high doses of a BPA, activated prothrombin complex concentrate, when used to treat breakthrough bleeds.
HAVEN 2 Study
HAVEN 2 is a single-arm, multicentre, open-label, global phase III study evaluating the efficacy, safety, and pharmacokinetics of emicizumab once weekly subcutaneous injection in paediatric patients with haemophilia A with inhibitors to factor VIII.
The interim analysis was conducted with 19 children younger than 12 years of age with haemophilia A with inhibitors who require treatment with BPAs. The median observation time was 12 weeks.
Summary of results
- Only one of 19 children receiving emicizumab reported a treated bleed. There were no reported joint or muscle bleeds.
- An intra-patient comparison (n=8) in patients who were previously enrolled in the NIS showed that all patients experienced zero treated bleeds or a 100% reduction after emicizumab treatment (previous annualized bleeding rate ranged from 0 to 34.24); this included seven children who had received prior BPA prophylaxis, and one who had received prior on-demand BPA.
- Data indicated that the same dose of emicizumab is appropriate for children as for adults and adolescents, based on the levels of emicizumab in the blood (pharmacokinetics) of the children compared with the level of emicizumab in the blood of adults and adolescents.
- The most common AEs with emicizumab in the HAVEN 2 study were mild injection site reactions and common cold symptoms (nasopharyngitis).
Summary of the HAVEN 1 (NCT02622321) study results to be presented at ISTH
|Study Description||Phase III randomised, multicenter, open-label study evaluating the efficacy, safety, and pharmacokinetics of emicizumab prophylaxis versus no prophylaxis in people with hemophilia A with inhibitors to factor VIII.|
Patients with hemophilia A with inhibitors aged ≥12 years on
episodic or prophylactic treatment with bypassing agent(s)
|Treated bleeds ABR (primary endpoint)|
Annualized bleeding rate [ABR]*
|% reduction (RR, p-value)||
(Interquartile range; IQR)
|% patients with zero bleeds (95% CI)||
Treated bleeds ABR intra-patient comparison
(Arm C patients who participated in NIS n=24; secondary endpoint)
|Study group||Prior prophylaxis with BPAs||Emicizumab prophylaxis|
|% reduction (RR, p-value)||
|Median ABR (IQR)||
12.0 [5.73; 24.22]
|0.0 [0.00; 2.23]|
|% patients with zero bleeds||
*Negative binomial regression model
Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are
collaborating to develop new pharmaceuticals and laboratories in Ukima
are conducting research for technology development for industrial
production. Overseas, Chugai
Pharmabody Research based in Singapore is engaged in research
focusing on the generation of novel antibody drugs by utilizing Chugai’s
proprietary innovative antibody engineering technologies. Chugai
Pharma USA and Chugai
Pharma Europe are engaged in clinical development activities in the
United States and Europe.
The consolidated revenue in 2016 of Chugai totalled 491.8 billion yen and the operating income was 80.6 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english.
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
More Than Half of Sub-Saharan Africa to Be Connected to Mobile by 2025, Finds New GSMA Study17.7.2018 10:00 | Tiedote
More than half the population of Sub-Saharan Africa will be subscribed to a mobile service by 2025, according to the latest edition of the GSMA’s Mobile Economy report series, published at the GSMA ‘Mobile 360 – Africa’ event being held in Kigali this week. The new report forecasts that there will be 634 million unique mobile subscribers1 across Sub-Saharan Africa by 2025, equivalent to 52 per cent of the population, up from 444 million (44 per cent) at the end of last year. The report also calculates that the mobile ecosystem will add more than $150 billion in value to Sub-Saharan Africa’s economy by 2022, equivalent to almost 8 per cent of regional GDP. “For many citizens across the region, particularly those living in rural areas, a mobile phone is not just a communications device but also the primary channel for getting online and a vital tool for improving their lives,” commented John Giusti, Chief Regulatory Officer at the GSMA. “More needs to be done to extend connectivity to th
Norsk Titanium Marks Milestone in U.S. Production17.7.2018 10:00 | Tiedote
The University of Notre Dame Turbomachinery Laboratory (NDTL), Norsk Titanium US, Inc. (Norsk), Pratt & Whitney and TURBOCAM International are collaborating to develop and test additively manufactured turbomachinery components. This collaboration will focus on exploring the applicability of Norsk’s Rapid Plasma Deposition™ (RPD™) material to turbomachinery applications. As part of this effort, NDTL will test an additively manufactured integrally bladed rotor (IBR) produced and inspected to meet the applicable quality specifications used in Pratt & Whitney’s current turbomachinery components. The team has completed the initial phase of testing, with TURBOCAM International conducting machining trials of Norsk’s RPD™ material, and Pratt & Whitney successfully inspecting the material to the same specification as forged turbomachinery components. The material’s manufacturing qualities were evaluated for applicability to TURBOCAM’s precision milling processes. “We were very pleased with the
GSMA Finds That Consumers in Developing Countries Are Hard Hit by High Spectrum Prices17.7.2018 09:00 | Tiedote
Better spectrum pricing policies are needed in developing countries to improve the economic and social welfare of the billions of people that remain unconnected to mobile broadband services, according to a new report, ‘Spectrum Pricing in Developing Countries’, released by the GSMA today at the Mobile 360 – Africa conference in Kigali. The study reveals that spectrum prices in developing countries are, on average, more than three times higher than in developed countries, when income is taken into account. This high spectrum pricing is a major roadblock to increasing mobile penetration. Authored by GSMA Intelligence, the study also found that governments are playing an active role in increasing spectrum prices to maximise state revenues from spectrum licensing. High spectrum prices are linked to countries with high levels of sovereign debt, and alarmingly average reserve prices in spectrum auctions are more than five times higher in developing countries than in developed, once income is
NEC and dotData Use AI to Accelerate Data Science for the SMBC Group17.7.2018 07:38 | Tiedote
NEC Corporation (NEC) (TOKYO:6701) and dotData, Inc., a Silicon Valley venture in the automation of data science, today announced the provision and full operation of “dotData” platform for the Sumitomo Mitsui Financial Group, Inc. (SMBC Group) in order to strengthen the Group’s analytical capabilities. In recent years, the need for big data analytics has been growing rapidly. However, there is also an increasing shortage of data scientists to handle this need. In order to address this issue, dotData automates data science processes through artificial intelligence (AI). dotData platform is now commercially available globally. NEC has obtained an exclusive license from dotData to provide this software across Japan. Sumitomo Mitsui Banking Corporation, NEC and the dotData team have actively worked to incorporate AI into banking operations in order to create new service offerings since 2016. Following this success, the SMBC Group is now expanding the provision of dotData platform throughou
Cushman & Wakefield To Acquire Its Irish Affiliate From Sherry FitzGerald Group16.7.2018 16:49 | Tiedote
Global real estate services firm Cushman & Wakefield today announces it has entered into a definitive agreement to acquire the commercial property arm of Sherry FitzGerald Group in the Republic of Ireland. The deal is expected to complete in early September 2018. Cushman & Wakefield already has a 20% stake in the Irish commercial property business which operated as its exclusive affiliate in the Republic – rebranding two years ago as Cushman & Wakefield Ireland. The firm, which has more than 100 commercial property professionals and offices in Dublin, Limerick and Galway, will now be fully integrated into Cushman & Wakefield, one of the world’s largest real estate services firms with 48,000 employees in approximately 400 offices and 70 countries. Managing Director Aidan Gavin becomes Cushman & Wakefield’s Head of Ireland and will also sit on the firm’s UK & Ireland Executive Committee. Cushman & Wakefield will maintain its close affiliate relationship with the wider Sherry FitzGerald G
Fischer & Schickendantz and Solution Alliance SRL Adopt Andersen Brand in Uruguay16.7.2018 16:30 | Tiedote
Fischer & Schickendantz, led by Juan Federico Fischer, and Solution Alliance SRL, led by Juan Ignacio Troccoli, have rebranded this week as Andersen Tax & Legal, a member firm of Andersen Global. The firm, based in Montevideo, entered a Collaboration Agreement with Andersen Global in September 2017, and is now a fully integrated member of the global verein. Juan Federico Fischer remarked, “Andersen is a symbol of quality and is recognized worldwide by both clients and professionals, and is ahead of the game in terms of creating a global firm with integrated tax and legal services. We are truly excited to officially be part of the team.” “Throughout their time with us as a collaborating firm and now a member firm, the team in Uruguay has demonstrated a deep commitment to providing seamless, best-in-class service. Additionally, Juan Federico is a member of Andersen Global’s Latin American regional board, and is the true embodiment of the values that our organization represents. I look fo
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme